33358942Sarraju A, Li J, Cannon CP, Chang TI, Agarwal R, Bakris G, Charytan DM, de Zeeuw D, Greene T, Heerspink HJL, Levin A, Neal B, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Perkovic V, Jardine M, Mahaffey KWAmerican heart journalCanagliflozin; Diabetes Mellitus, Type 2; Heart Failure; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 InhibitorsAdrenergic beta-Antagonists; Age Factors; Aged; Cardiovascular Diseases; Diuretics; Double-Blind Method; Female; Humans; Male; Middle Aged; Placebos; Sex FactorsEffects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am Heart J. 2021 03; 233:141-148.Am Heart J2020-12-22T00:00:002020Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.prns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000367Concepts & Ideas62718420.694053Age FactorsD000368Living Beings1341183530.29479AgedD000319Chemicals & Drugs591520.904018Adrenergic beta-AntagonistsD004232Chemicals & DrugsPhysiology331240.942334DiureticsD002318Disorders2368260.581898Cardiovascular DiseasesD003924Disorders21613720.492478Diabetes Mellitus, Type 2D004311Procedures33818220.70897Double-Blind MethodD006333Disorders18711960.4939Heart FailureD008875Concepts & IdeasLiving Beings1473249570.258834Middle AgedD005260Physiology1992444050.191184FemaleD006801Living Beings2262862810.130064HumansD008297Physiology1931408600.201635MaleAuthorship 14300560.199350.199351authors10.2516has subject areaD051436Disorders893500.686527Renal Insufficiency, ChronicD010919DevicesProcedures982180.94867PlacebosD012737Concepts & Ideas44110530.766363Sex FactorsD0000688961310.98053CanagliflozinUniversity of ChicagoGeorgeBakris0GBoa7McCszMknJtY0fp/Cv/+94=George Bakris41.78927490000000-87.601250000000001393Bakris, GeorgeProfessortrue1ProfessorProfessorMedicine-Endocrinology